Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1993 5
1994 3
1995 11
1996 1
1997 7
1998 11
1999 7
2000 7
2001 16
2002 9
2003 14
2004 18
2005 14
2006 19
2007 28
2008 25
2009 19
2010 22
2011 24
2012 39
2013 48
2014 47
2015 56
2016 32
2017 48
2018 61
2019 81
2020 117
2021 122
2022 137
2023 112
2024 145
2025 72

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,239 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Methionine secreted by tumor-associated pericytes supports cancer stem cells in clear cell renal carcinoma.
Zhang C, Du Z, Gao Y, Lim KS, Zhou W, Huang H, He H, Xiao J, Xu D, Li Q. Zhang C, et al. Cell Metab. 2024 Apr 2;36(4):778-792.e10. doi: 10.1016/j.cmet.2024.01.018. Epub 2024 Feb 19. Cell Metab. 2024. PMID: 38378000 Free article.
Here, we identify a subset of vascular pericytes, defined by expression of platelet-derived growth factor receptor beta (PDGFR-beta) and G-protein-coupled receptor 91 (GPR91), that promote tumorigenesis and tyrosine kinase inhibitors (TKIs) resistance by functioning as the primar …
Here, we identify a subset of vascular pericytes, defined by expression of platelet-derived growth factor receptor beta (PDGFR-beta) and G-p …
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Lee CH, et al. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298296 Free PMC article. Clinical Trial.
PURPOSE: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients had advanced non-clear-cell renal ca …
PURPOSE: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell …
Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma.
Riscal R, Bull CJ, Mesaros C, Finan JM, Carens M, Ho ES, Xu JP, Godfrey J, Brennan P, Johansson M, Purdue MP, Chanock SJ, Mariosa D, Timpson NJ, Vincent EE, Keith B, Blair IA, Skuli N, Simon MC. Riscal R, et al. Cancer Discov. 2021 Dec 1;11(12):3106-3125. doi: 10.1158/2159-8290.CD-21-0211. Cancer Discov. 2021. PMID: 34244212 Free PMC article.
Clear cell renal cell carcinoma (ccRCC) is characterized by large intracellular lipid droplets containing free and esterified cholesterol; however, the functional significance of cholesterol accumulation in ccRCC cells is unknown. ...Blocking ch …
Clear cell renal cell carcinoma (ccRCC) is characterized by large intracellular lipid droplets containing …
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.
Tan SK, Hougen HY, Merchan JR, Gonzalgo ML, Welford SM. Tan SK, et al. Nat Rev Urol. 2023 Jan;20(1):48-60. doi: 10.1038/s41585-022-00654-6. Epub 2022 Oct 3. Nat Rev Urol. 2023. PMID: 36192502 Free PMC article. Review.
Lipid droplet formation is a defining histological feature in clear-cell renal cell carcinoma (ccRCC) but the underlying mechanisms and importance of this biological behaviour have remained enigmatic. ...Enzymes involved in the intrinsic FA meta …
Lipid droplet formation is a defining histological feature in clear-cell renal cell carcinoma (ccRCC) but …
Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma.
Riscal R, Gardner SM, Coffey NJ, Carens M, Mesaros C, Xu JP, Xue Y, Davis L, Demczyszyn S, Vogt A, Olia A, Finan JM, Godfrey J, Schultz DC, Blair IA, Keith B, Marmorstein R, Skuli N, Simon MC. Riscal R, et al. Cancer Res. 2024 May 15;84(10):1570-1582. doi: 10.1158/0008-5472.CAN-23-0821. Cancer Res. 2024. PMID: 38417134 Free PMC article.
Clear cell renal cell carcinoma (ccRCC) incidence has risen steadily over the last decade. ...SIGNIFICANCE: The bile acid biosynthetic enzyme HSD3B7 is essential for ccRCC cell survival and can be targeted to induce accumulation of choles …
Clear cell renal cell carcinoma (ccRCC) incidence has risen steadily over the last decade. ...SIGNIFICANC …
Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.
Jiang Z, Wang J, Dao C, Zhu M, Li Y, Liu F, Zhao Y, Li J, Yang Y, Pan Z. Jiang Z, et al. Apoptosis. 2024 Jun;29(5-6):681-692. doi: 10.1007/s10495-023-01932-3. Epub 2024 Jan 28. Apoptosis. 2024. PMID: 38281281
Kidney renal clear cell carcinoma (KIRC) is the most common histopathologic type of renal cell carcinoma. PANoptosis, a cell death pathway that involves an interplay between pyroptosis, apoptosis and necroptosis, is associat …
Kidney renal clear cell carcinoma (KIRC) is the most common histopathologic type of renal cell …
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Dror Michaelson M, Appleman LJ, Roy A, Perini RF, Liu Y, Choueiri TK. Jonasch E, et al. Eur J Cancer. 2024 Jan;196:113434. doi: 10.1016/j.ejca.2023.113434. Epub 2023 Nov 15. Eur J Cancer. 2024. PMID: 38008031 Clinical Trial.
BACKGROUND: Accumulation of the HIF-2alpha transcription factor is an oncogenic event implicated in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). In the phase I LITESPARK-001 study, the first-in-class HIF-2alpha inhibitor belzuti …
BACKGROUND: Accumulation of the HIF-2alpha transcription factor is an oncogenic event implicated in the tumorigenesis of clear cel …
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Motzer RJ, et al. Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7. Lancet Oncol. 2022. PMID: 35688173 Free PMC article. Clinical Trial.
BACKGROUND: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median fo …
BACKGROUND: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall surviva …
Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization.
Zheng X, Wang Y, Qiu X. Zheng X, et al. Eur J Pharmacol. 2024 Oct 5;980:176840. doi: 10.1016/j.ejphar.2024.176840. Epub 2024 Jul 20. Eur J Pharmacol. 2024. PMID: 39038636
This study is the first to comprehensively analyse the role of MAPK-family genes in the progression, prognosis, immune-cell infiltration, methylation, and potential therapeutic value drug candidates in ccRCC. ...Model construction, evaluation, and external validatio …
This study is the first to comprehensively analyse the role of MAPK-family genes in the progression, prognosis, immune-cell in …
Clear cell papillary renal cell carcinoma: an update after 15 years.
Williamson SR. Williamson SR. Pathology. 2021 Jan;53(1):109-119. doi: 10.1016/j.pathol.2020.10.002. Epub 2020 Nov 19. Pathology. 2021. PMID: 33223139 Review.
Fifteen years since the first recognition of clear cell papillary renal cell carcinoma, this distinct renal tumour type is now well accepted as a distinct entity in major classification schemes. ...Potential mimics include clear …
Fifteen years since the first recognition of clear cell papillary renal cell carcinoma, this distinct …
1,239 results